Molecules, Vol. 29, Pages 1859: A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action
Molecules, Vol. 29, Pages 1859: A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action
Molecules doi: 10.3390/molecules29081859
Authors:
Shiqin Zhang
Xiaoling Ren
Bingzheng Zhang
Tian Lan
Bing Liu
Nonalcoholic fatty liver disease (NAFLD) is the liver component of a cluster of conditions, while its subtype, nonalcoholic steatohepatitis (NASH), emerges as a potentially progressive liver disorder that harbors the risk of evolving into cirrhosis and culminating in hepatocellular carcinoma (HCC). NASH and cardiovascular disease (CVD) have common risk factors, but compared to liver-related causes, the most common cause of death in NASH patients is CVD. Within the pharmacological armamentarium, statins, celebrated for their lipid-modulating prowess, have now garnered attention for their expansive therapeutic potential in NASH. Evidence from a plethora of studies suggests that statins not only manifest anti-inflammatory and antifibrotic properties but also impart a multifaceted beneficial impact on hepatic health. In this review, we used “statin”, “NAFLD”, “NASH”, and “CVD” as the major keywords and conducted a literature search using the PubMed and Web of Science databases to determine the safety and efficacy of statins in patients and animals with NASH and NAFLD, and the mechanism of stat...
Source: Molecules - Category: Chemistry Authors: Shiqin Zhang Xiaoling Ren Bingzheng Zhang Tian Lan Bing Liu Tags: Review Source Type: research
More News: Cancer & Oncology | Carcinoma | Cardiology | Cardiovascular | Chemistry | Cholesterol | Cirrhosis | Databases & Libraries | Fatty Liver Disease (FLD) | Heart | Hepatocellular Carcinoma | Liver | Liver Cancer | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Science | Statin Therapy | Study | Urology & Nephrology